First pharmacogenomic CYP450 test designed for clinic use

29 March 2005. Related: Other news.

The AmpliChip CYP450 Test is powered by Affymetrix technology. It provides comprehensive coverage of gene variations – including deletions and duplications – for the 2D6 and 2C19 genes, which play a role in the metabolism of about 25% of all prescription drugs.

It is intended to be an aid for physicians in individualizing treatment doses for patients on therapeutics metabolised through these genes.

Comment

This Roche assay only looks at the CYP450 2D6 and 2C19 systems at this time. Although most of the problematic ARVs are metabolized by the 3A4 system, this test might be useful for methadone, some OI treatments and maybe TMC114, which is a sulfonamide.

This useful table gives an indication of the complexity of the CYP450 and the medicines and foods that induce or inhibit individual systems.
www.edhayes.com/CYP450-2.html